The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $8.35

Today's change-1.10 -11.64%
Updated November 17 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $8.35

Today's change-1.10 -11.64%
Updated November 17 4:00 PM -5GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc down (U.S.)$1.10

Coherus BioSciences Inc closed sharply lower Friday, dropping (U.S.)$1.10 or 11.64% to (U.S.)$8.35. Over the last five days, shares have lost 16.92% and sit 3.09% above their 52-week low. This security has underperformed the S&P 500 by 88.09% during the last year.

Key company metrics

  • Open(U.S.) $9.35
  • Previous close(U.S.) $9.45
  • High(U.S.) $9.35
  • Low(U.S.) $8.10
  • Bid / Ask(U.S.) $7.15 / (U.S.) $15.75
  • YTD % change-70.34%
  • Volume1,250,691
  • Average volume (10-day)658,048
  • Average volume (1-month)573,528
  • Average volume (3-month)527,355
  • 52-week range(U.S.) $8.10 to (U.S.) $29.59
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.42
Updated November 17 4:00 PM -5GMT. Delayed by at least 15 minutes.
S&P TSX0.40%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue0101
Total other revenue--------
Total revenue0101
Gross profit--------
Total cost of revenue--------
Total operating expense57587374
Selling / general / administrative14241915
Research & development43355459
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-57-57-72-73
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-59-55-75-76
Income after tax-59-55-75-76
Income tax, total--------
Net income-59-55-75-76
Total adjustments to net income--------
Net income before extra. items-59-55-75-76
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-59-55-75-76
Inc. avail. to common incl. extra. items-59-55-75-76
Diluted net income-59-55-75-76
Dilution adjustment--------
Diluted weighted average shares54514944
Diluted EPS excluding extraordinary itemsvalue per share-1.09-1.08-1.54-1.71
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-1.09-1.07-1.54-1.71